Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host

2004 • 1,358 citations

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

2008 • 1,347 citations

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

2001 • 1,296 citations

Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis

2003 • 1,223 citations

A Prospective Study of Cholesterol, Apolipoproteins, and the Risk of Myocardial Infarction

1991 • 1,184 citations

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

2008 • 1,057 citations

Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis

2003 • 922 citations

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

2008 • 826 citations

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

2004 • 818 citations

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial

2004 • 790 citations

Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

2006 • 783 citations

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

2007 • 734 citations

Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review

2008 • 671 citations

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

2007 • 542 citations

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study

2008 • 463 citations

C-Reactive Protein

2003 • 425 citations

Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes

2001 • 383 citations

Cardiology Patient Page

2001 • 300 citations

Macropinocytosis Is the Endocytic Pathway That Mediates Macrophage Foam Cell Formation with Native Low Density Lipoprotein

2004 • 266 citations

Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease<subtitle>Large-Scale Prospective Data</subtitle>

2008 • 262 citations

Inflammation: A pivotal link between autoimmune diseases and atherosclerosis

2006 • 257 citations

Lipid profiles in untreated patients with rheumatoid arthritis.

1999 • 252 citations

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis

2006 • 223 citations

Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

2007 • 198 citations

Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study

2002 • 177 citations

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

2007 • 154 citations

Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation

2004 • 150 citations

Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation

2005 • 136 citations

Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.

2005 • 130 citations

Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis

2006 • 124 citations

Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.

2006 • 123 citations

Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions

2005 • 114 citations

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

2007 • 112 citations

Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis

2007 • 101 citations

Serum lipids and disease severity in children with severe meningococcal sepsis*

2005 • 100 citations

Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.

2006 • 96 citations

Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis

2006 • 96 citations

C-reactive protein and cardiovascular disease: Weighing the evidence

2006 • 85 citations

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

2006 • 84 citations

Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.

2002 • 77 citations

Lipoprotein(a) and Lipids in Relation to Inflammation in Rheumatoid Arthritis

2000 • 75 citations

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

2005 • 71 citations

Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody

2008 • 69 citations

Postsurgical reduction of serum lipoproteins: Interleukin-6 and the acute-phase response

1998 • 68 citations

Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis

2007 • 66 citations

Dyslipidemia in the Critically Ill

2006 • 65 citations

Changes in serum lipids and lipoproteins in cancer patients during chemotherapy

1992 • 64 citations

Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system.

1982 • 50 citations

Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.

2007 • 46 citations

Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis

1993 • 46 citations

Dyslipoproteinaemia in patients with active, chronic polyarthritis. a study on serum lipoproteins and triglyceride clearance (intravenous fat tolerance test)

1977 • 39 citations

RAPID: rheumatoid arthritis.

2007 • 22 citations

Testosterone deficiency: which patients should you screen and treat?

2007 • 9 citations

Cited By (0)

Loading...